Agoracom Blog Home

Posts Tagged ‘stocks’

$HPQ.ca Gen1 Nano Silicon Reactor Exceeds Expectations, Produces Sub 100 Nm Spherical #Nanopowders & #Nanowires $ENPH $BE $NNO.ca $PYR.ca

Posted by AGORACOM-JC at 8:18 AM on Thursday, January 21st, 2021

Low-Cost Manufacturing of Nano Silicon Materials

  • Gen1 NSiR system performance exceeded design and modelling expectations:
    • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires.
    • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.

MONTREAL, Jan. 21, 2021 — Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or “the Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC : URAGF ), through its wholly – owned subsidiary, HPQ Nano Silicon Powders inc (“HPQ NANO”), is pleased to update shareholders on milestones achieved during ongoing Gen1 PUREVAP TM Nano Silicon Reactor (“NSiR”) commissioning tests conducted by technology provider PyroGenesis Canada Inc. ( TSX: PYR ) .

“With the Gen1 PUREVAP TM NSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications, as we continue working on scaling up the capabilities of our PUREVAP TM NSiR process.” said Bernard Tourillon, President and CEO HPQ Silicon.

PUREVAP TM NSiR LOW-COST PROCESS: FIRST RESULTS ENCOURAGING, MORE TESTING TO FOLLOW

The material produced, under the less than optimum operating conditions of the first commissioning tests, was analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD) and yielded the following information:

  • Gen1 NSiR system performance exceeded design and modelling expectations:
    • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires.
    • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.
  • SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.
  • Samples from these commissioning tests have been sent to Professor Lionel ROUÉ of the Centre Énergie Matériaux Télécommunications (EMT) for electro-chemical evaluation.
  • Using results from data collected during these preliminary tests, PyroGenesis technical team has improved the design of the system and the operational parameters of the reactor.
    • It will be possible to provide further inputs and controls on the process to customize the composition and size of the spherical nano powders and nano wires.
  • The Gen1 NSiR is now ready to commence further testing of Silicon nano materials under new conditions, with a goal of producing larger size Silicon (Si) nanopowders and nanowires.

A METHODICAL APPROACH TO THE COMMERCIAL DEVELOPMENT OF OUR DISRUPTIVE TECHNOLOGY

Despite massive investment in Silicon material for batteries , current manufacturing processes are simply not scalable or commercially viable. The PUREVAP TM NSiR represents a game changing leap forward in resolving the issues of commercial viability and scalability, and with the Gen1 NSiR now operational, HPQ NANO is uniquely well positioned to offer industry participants a wide spectrum of products for testing.

The scale of the Gen1 PUREVAP TM NSiR allows HPQ NANO technical provider PyroGenesis to take full advantage of a quick R&D feedback loop during the testing phase. Over short periods, tests are completed, material produced is analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD), operational parameters are reviewed and system modifications and/or operational improvements are implemented. This is the key to our methodical approach of developing a truly disruptive low-cost technology that is going to change nano silicon materials manufacturing.

Tourillon added HPQ’s Silicon R&D consortium has the depth and flexibility to meet the challenges as we strive to produce products for renewable energy storage participants and electric vehicle manufacturers, who are searching for cost effective ways of increasing the Silicon contained in their batteries . Silicon’s potential to meet energy storage demand is undeniable, generating massive investments , and serious industry interest. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”

Read More: https://agoracom.com/ir/HPQ-SiliconResources/forums/discussion/topics/753558-hpq-gen1-nano-silicon-reactor-exceeds-expectations-produces-sub-100-nm-spherical-nanopowders-nanowires/messages/2299217#message

Victory Square Technologies $VST.ca $VSQTF Portfolio Company, Immersive Tech, Announces the Creation of World’s First #COVID-safe Location-Based Entertainment (LBE) Virtual Reality #VR Division “UNCONTAINED” $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 8:42 AM on Wednesday, January 20th, 2021
Victory Square Technologies | LinkedIn
  • Company launches first-ever COVID-safe location-based (LBE) Virtual Reality attractions division “UNCONTAINED” to disrupt the marketplace and fulfill demand from its Family Entertainment Center (FEC) clients.
  • Immersive Tech is planning for a public listing in the first half of 2021.
  • Leading immersive experience company builds upon current and past relationships with major companies.
  • Announcement brings creation of the world’s first-ever free-roam interactive VR franchise attraction available for rapid sale to the global attraction and entertainment marketplace.

VANCOUVER, British Columbia, Jan. 20, 2021 — Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) , a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that its portfolio company Immersive Tech (“Company”) has launched a premiere new Location-Based Entertainment (LBE) VR attractions division named UNCONTAINED to capitalize on the growing demand for COVID-safe attractions. UNCONTAINED will be the world’s first free-roam interactive VR franchise attraction, built for a COVID world within shipping containers. The experience will allow for up to six players to roam freely within the container while interacting inside a digital environment as a team while making decisions that help guide and define the story.

Immersive Tech designs, engineers and builds custom technology-driven experiences, whether they facilitate brand integration or are aiming to create the best real life adventure possible. The Company recently announced the creation of three unique entertainment escape rooms custom designed and built for Apex Entertainment’s new location in Virginia Beach VA, USA. The three custom room themes include an underwater submarine adventure, a post-war bunker experience, and an AI-controlled warship gone rogue featuring a race against time and a family-friendly focus.

“UNCONTAINED” leverages the manner of design experience that Immersive Tech has gained and honed over the past four years in creating and launching highly successful interactive escape rooms for Family Entertainment Centers. This is complemented by a fundamental understanding of shipping containers as highlighted in their recent 3-room escape experience for Leaps by Bayer, a Bayer Pharmaceutical company, in 2020.

Read More: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/753450-victory-square-technologies-portfolio-company-immersive-tech-announces-the-creation-of-world-s-first-covid-safe-location-based-entertainment/messages/2299018#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Advances BioCloud Technology for European Sales and Provides Update $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 7:48 AM on Wednesday, January 20th, 2021
kontrol-logo
  • Announced that it continues to advance the deployment of its BioCloud technology
  • Initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications
  • In the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications
  • “We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

TORONTO, ON / January 20, 2021 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that it continues to advance the deployment of its BioCloud technology.

“We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

Non-Disclosure Agreement (NDA)

BioCloud has entered into a Non-Disclosure Agreement, with a leading medical sports authority, to share the full scope of BioCloud’s patents and research. The purpose of the NDA is to advance various potential sport applications. Such applications include, but are not limited to, dressing rooms and training facilities.

BioCloud European Standards

Kontrol has initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications, which is an important prerequisite for European sales. As part of the product requirements for each country within the European Union there may be further standards approval required but these will be dealt with on a case-by-case basis.

Distribution Network

Kontrol has recently added a South Korean firm to its growing distribution network and is in discussion with numerous interested parties.

Viral/Pathogen Advisory Committee

Kontrol is in the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications. Kontrol seeks to establish the committee in February 2021.

Corporate Name Change

Kontrol’s corporate name change to Kontrol Technologies Corp. is anticipated to be completed by the end of January 2021. There has been no specific delay in the process other than the time it takes to complete filings between B.C. and Ontario corporate registries and all of the associated requirements.

About Kontrol BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

Read More: https://agoracom.com/ir/KontrolEnergy/forums/discussion/topics/753445-kontrol-advances-biocloud-technology-for-european-sales-and-provides-update/messages/2299011#message

VIDEO – Valeo Pharma $VPH.ca $VPHIF Starts Off 2021 With A Bang As MDBriefcase Validates Key Ingredients In Its Immune System Support Product $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma (@valeo_pharma) | Twitter

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • $5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
  • 9 products currently in the market with an annual estimated peak sales of $40M/year
  • 7 products in the pipeline with an annual estimated peak sales of $45M/year

In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:

  • $6.9M Bought Deal financing at $1.20/shares
  • A $1.7M Oversubscribed debenture (non-convertible) 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight. 

Saviuk agreed and gave the following reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

Well there you have it.  Valeo is a great story. Watch the video.

HOLD ON. THERE’S MORE … A LOT MORE

In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease.  What does this mean?

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
  • Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.

Now you have it.  That’s the Valeo story as it applies to just 2 of their amazing products.  There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

Victory Square $VST.ca $VSQTF Technologies Signs Binding Letter of Intent to Acquire IV Hydreight, An On-Demand & On-Site Mobile #Health, #Pharmaceutical & #Wellness Service Provider Across the United States $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, January 19th, 2021
Victory Square Technologies | LinkedIn
  • Hydreight provides a completely compliant turnkey business model for health professionals to offer fully licensed medical, health & wellness services through an on-demand and on-site platform.

  • In addition to providing telehealth services, Hydreight also provides a diverse suite of health & wellness protocols that include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments.

  • Hydreight is a USA certified e-script and telemedicine provider, allowing Hydreight to offer a wide array of health and medical services in all 50 states.

  • Hydreight provides full pharmaceutical offerings across the United States (Hydreight has full 503B Pharmaceutical supply capabilities ).
  • Hydreight has established key relationships and supply network chains with major vendors including: Medline, Mckesson, Allergan (Botox), Galderma and numerous pharmacies.

VANCOUVER, British Columbia, Jan. 19, 2021 — Victory Square Technologies Inc. (” Victory Square ” or the “ Company ”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that it has signed a binding letter of intent (the “ LOI ”) dated January 13, 2021 in respect of the acquisition (the “ Acquisition ”) of all of the shares of IV Hydreight Inc. (“ Hydreight ”), a mobile health and wellness service provider operating in the United States.

Founded in 2018, Hydreight provides a unique, custom built, proprietary telemedicine service that allows users to book confidential health & wellness and/or medical services at their home, hotel, office or wherever they may need discreet assistance. The business model of Hydreight leverages decentralized healthcare to bring quality telehealth, medical, health and wellness services to the masses in an efficient, scalable and cost effective way.

Read More: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/753355-victory-square-technologies-signs-binding-letter-of-intent-to-acquire-iv-hydreight-an-on-demand-on-site-mobile-health-pharmaceutical-wellness/messages/2298763#message

Former #LifeLabs COO Joins Novamind $NM.ca Leadership Team $RVV.ca $MMED $PSYC.ca

Posted by AGORACOM-JC at 8:05 AM on Tuesday, January 19th, 2021

Pierre Bou-Mansour is former COO of LifeLabs, one of Canada’s largest medical service companies

  • Announced the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer.
  • Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.
  • Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents.
  • In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.

TORONTO, ON / January 19, 2021 / Novamind Inc., (CSE:NM) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.

An accomplished senior executive and leader, Pierre brings a wealth of experience managing large and complex healthcare organizations. Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents. In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.

Pierre Bou-Mansour said, “Novamind’s Cedar Psychiatry clinics and Cedar Clinical Research sites are both well-positioned to scale as regulated access to psychedelic medicine continues to expand rapidly in jurisdictions around the world. I look forward to working with the leadership team to ensure strategic expansion of our operating model for clinical care and clinical research in psychedelic medicine.”

Pierre has a proven track record for growing and transforming healthcare companies. He spent eight years at LifeLabs, serving as the COO from 2017 to 2019, and successfully led the integration of two acquired competitors. During this period, LifeLabs grew into one of the largest medical service companies in Canada, with over 5,700 employees, 370 patient access sites, and over US $977 million in annualized revenue (dnb.com).

Yaon Conforti, Chief Executive Officer and Director of Novamind added, “Pierre brings a distinguished operational track record in healthcare to drive the expansion of Novamind’s network of mental health clinics and clinical research sites. His role is critical as we execute against our pipeline of growth opportunities.”

KWESST $KWE.ca Enters into Non-Lethal Technology Purchase Agreement $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 8:34 AM on Monday, January 18th, 2021
  • Entered into a technology purchase agreement with DEFSEC Corporation to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology
  • The LEC Technology is a proprietary non-lethal cartridge-based ordnance system.
  • DEFSEC is an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST.

Ottawa, Ontario–(January 18, 2021) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced it has entered into a technology purchase agreement (the “Purchase Agreement”) with DEFSEC Corporation (“DEFSEC”) to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology (“LEC Technology”). The LEC Technology is a proprietary non-lethal cartridge-based ordnance system. DEFSEC is an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST.

“We see the LEC Technology as having universal application across four market segments that currently use a variety of dated “non-lethal” or “less-lethal” products, each having a vast global market. These segments are (i) public order (riots and control of dangerous subjects), (ii) military and law enforcement training (realistic force-on-force training), (iii) personal defence (home, car, boat, RV, camping, hiking), and (iv) high-action gaming,” said Jeff MacLeod, KWESST Founder and CEO. “The kind of fatalities that have led to widespread protests in the U.S. are just one example of the need for more advanced solutions that enable law enforcement to engage with more benign devices from a safer stand-off distance and ensure that everyone goes home alive.”

The market development of the LEC Technology will benefit from the deep combined experience of Jeff MacLeod and David Luxton in the specialty ordnance business. Mr. MacLeod is a highly knowledgeable defence industry executive with over 20 years’ experience in the field of small arms and advanced soldier systems. Prior to establishing KWESST, he was the General Manager of Colt Canada, the primary supplier of small arms to the Canadian military. David Luxton was the founder in 1990 of Simunition Inc., a business that develops and sells simulated munitions for realistic close quarters combat training for military and law enforcement around the world. He sold the business to a large military contractor and from 2015 – 2018 he was the Executive Chairman of United Tactical Systems LLC, a U.S. company that develops and sells products for the global less-lethal market.

Read More: https://agoracom.com/ir/Kwesst/forums/discussion/topics/753252-kwesst-enters-into-non-lethal-technology-purchase-agreement/messages/2298557#message

ZeUPay: Groundbreaking P2P Payment Provider & #Crypto to Fiat Gateway – $ZEU.ca Technologies $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

Posted by AGORACOM-JC at 7:26 AM on Monday, January 18th, 2021
  • Completed its exhaustive due diligence review and corporate integration documentation and expects delivery of final legal opinions in relation to the proposed acquisition of Prego International Group AS.
  • ZeUPay will be fully integrated into the Mula ecosystem.
  • Users of ZeU and the Mula platform native function and applications, as well as users of third-party developed applications, will be able to use its Crypto to Fiat gateway functionalities.

Montréal – January 17, 2021 – ZeU Technologies Inc. (CSE:ZEU) (CNSX:ZEU.CN) is pleased to announce that it has completed its exhaustive due diligence review and corporate integration documentation and expects delivery of final legal opinions in relation to the proposed acquisition of Prego International Group AS.

Management of both companies plan to sign the final acquisition documents later this week. It is expected that all regulatory review should be completed on or around February 5,  2021.  At that point, all shares of Prego International would have been exchanged for convertible debentures of ZeUPay, a wholly owned subsidiary of ZeU Technologies and the target corporation.

Ronald Eriksen will join the board of directors of ZeU Technologies at closing.

ZeUPay will be fully integrated into the Mula ecosystem. Users of ZeU and the Mula platform native function and applications, as well as users of third-party developed applications, will be able to use its Crypto to Fiat gateway functionalities.  All current account holders of Prego, including Pay2Go card holders, will be seamlessly migrated to a Mula digital wallet that will allow them to send or receive money, lend to the ecosystem, earn income and interest, and structure transactions. ZeUPay’s utility token will be hot-swappable with a range of other tokens, including the MulaPay stable utility token.

Source: https://agoracom.com/ir/ZeUTechnologies/forums/discussion/topics/753243-zeupay-groundbreaking-p2p-payment-provider-crypto-to-fiat-gateway/messages/2298541#message

Valeo Pharma $VPH.ca $VPHIF Announces Major Addition to its Senior Management Team $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 7:14 AM on Monday, January 18th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Frederic Fasano named President and COO
  • Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors

MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.

“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk,  CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/753244-valeo-pharma-announces-major-addition-to-its-senior-management-team/messages/2298542#message

AGORACOM Small Cap 60: Valeo Pharma $VPH.ca $VPHIF Discusses Health Canada Approval for Redesca™ and Redesca Hp™ $30 Million Forecasted Annual Peak Sales $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:14 PM on Thursday, January 14th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Commercial launch to impact first half 2021 revenue
  • $30 million forecasted annual peak sales
  • 8 years of proven in-market safety Internationally
  • Low molecular weight heparin increasingly used to prevent COVID-19 driven complications

“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly  being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.

Hub On AGORACOM / Corporate Profile